6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine | 907203-87-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine
• 英文别名: 6-Chloro-n-(5-methyl-1h-pyrazol-3-yl)-3-nitropyridin-2-amine
• CAS: 907203-87-6
• 化学式: C₉H₈ClN₅O₂
• 分子量: 253.648
• InChiKey: NMNSTQIMHISZML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  99.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine 在 10% Pd/C 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 正丁醇 为溶剂， 反应 8.0h， 生成 N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(5-methyl-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine
  参考文献：
  名称：

  Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors

  摘要：

  Trk receptor tyrosine kinases have been implicated in cancer and pain. A crystal structure of TrkA with AZ-23 (1a) was obtained, and scaffold hopping resulted in two 5/6-bicyclic series comprising either imidazo[4,5-b]pyridines or purines. Further optimization of these two fusion series led to compounds with subnanomolar potencies against TrkA kinase in cellular assays. Antitumor effects in a TrkA-driven mouse allograft model were demonstrated with compounds 2d and 3a.

  DOI：

  10.1021/ml300074j
• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 、 3-氨基-5-甲基吡唑 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine
  参考文献：
  名称：

  Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors

  摘要：

  Trk receptor tyrosine kinases have been implicated in cancer and pain. A crystal structure of TrkA with AZ-23 (1a) was obtained, and scaffold hopping resulted in two 5/6-bicyclic series comprising either imidazo[4,5-b]pyridines or purines. Further optimization of these two fusion series led to compounds with subnanomolar potencies against TrkA kinase in cellular assays. Antitumor effects in a TrkA-driven mouse allograft model were demonstrated with compounds 2d and 3a.

  DOI：

  10.1021/ml300074j

文献信息

• Chemical Compounds - 759
  申请人：Astrazeneca AB

  公开号：US20140155394A1

  公开（公告）日：2014-06-05

  The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

  本发明涉及化合物的公式（I）：以及它们的制药组合物和使用方法。这些化合物提供了治疗骨髓增生性疾病和癌症的方法。
• 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
  申请人：Davies Audrey

  公开号：US20100324040A1

  公开（公告）日：2010-12-23

  The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

  本发明涉及式(I)的化合物，以及它们的制药组合物和使用方法。这些化合物提供了治疗骨髓增生性疾病和癌症的方法。
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1853588B1

  公开（公告）日：2008-06-18
• 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B]PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
  申请人：AstraZeneca AB

  公开号：EP2152705A1

  公开（公告）日：2010-02-17
• US8486966B2
  申请人：——

  公开号：US8486966B2

  公开（公告）日：2013-07-16